Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Endometrial cancer is a type of tumour that arises in the tissue lining the uterus. Most endometrial cancers are adenocarcinomas; that is, cancers formed from cells that make and release mucus and other fluids.
Single-cell profiling of uterine blood reveals neutrophil reprogramming and transcriptomic signatures that track endometrial cancer progression from premalignant lesions to invasive carcinoma.
Mirvetuximab soravtansine (MIRV) is an antibody drug conjugate comprised of a folate receptor alpha-targeted monoclonal antibody and the anti-tubulin maytansinoid payload, DM4. Here the authors report the results of a phase II trial of MIRV in combination with anti-PD1 pembrolizumab in patients with recurrent folate receptor alpha-positive uterine serous carcinoma.
In a recent study published in Nature Genetics, Kübler, Nardone et al. analysed the mechanisms underlying tamoxifen-associated uterine cancer and identified PI3K pathway activation as a key non-genetic driver.
Tamoxifen is an essential drug in breast cancer therapy. Unlike prevailing models of therapy-related tumorigenesis, tamoxifen acts by directly activating the PI3K pathway, bypassing the need for mutations in one of the most common driver genes in sporadic uterine cancer. These findings open avenues for investigating similar mechanisms in other drugs.
PapSEEK, a novel liquid-based cytology test, enabled the highly specific detection of endometrial and ovarian cancer in a retrospective study. Herein, I discuss potential applications of this tool, both for cancer screening of asymptomatic populations and for the early diagnosis of cancer in symptomatic women.
